NO321990B1 - Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15. - Google Patents
Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15. Download PDFInfo
- Publication number
- NO321990B1 NO321990B1 NO19973705A NO973705A NO321990B1 NO 321990 B1 NO321990 B1 NO 321990B1 NO 19973705 A NO19973705 A NO 19973705A NO 973705 A NO973705 A NO 973705A NO 321990 B1 NO321990 B1 NO 321990B1
- Authority
- NO
- Norway
- Prior art keywords
- monoclonal antibody
- antibody according
- treatment
- medicament
- antibodies
- Prior art date
Links
- 102000003812 Interleukin-15 Human genes 0.000 title claims description 81
- 108090000172 Interleukin-15 Proteins 0.000 title claims description 81
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 23
- 238000011282 treatment Methods 0.000 title claims description 17
- 239000003814 drug Substances 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 201000010099 disease Diseases 0.000 title description 15
- 238000002360 preparation method Methods 0.000 title description 5
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 15
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 208000024908 graft versus host disease Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 6
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 102000056003 human IL15 Human genes 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/392,317 US5795966A (en) | 1995-02-22 | 1995-02-22 | Antagonists of interleukin-15 |
PCT/US1996/002520 WO1996026274A1 (en) | 1995-02-22 | 1996-02-21 | Antagonists of interleukin-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO973705D0 NO973705D0 (no) | 1997-08-12 |
NO973705L NO973705L (no) | 1997-10-22 |
NO321990B1 true NO321990B1 (no) | 2006-07-31 |
Family
ID=23550114
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19973705A NO321990B1 (no) | 1995-02-22 | 1997-08-12 | Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15. |
NO20060194A NO20060194L (no) | 1995-02-22 | 2006-01-12 | Antagonister mot interleukin-15 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060194A NO20060194L (no) | 1995-02-22 | 2006-01-12 | Antagonister mot interleukin-15 |
Country Status (16)
Country | Link |
---|---|
US (5) | US5795966A (de) |
EP (2) | EP0811065B2 (de) |
JP (2) | JPH11500908A (de) |
KR (1) | KR19980702238A (de) |
AT (1) | ATE339505T1 (de) |
AU (1) | AU708549B2 (de) |
CA (2) | CA2637795C (de) |
DE (1) | DE69636538T3 (de) |
DK (1) | DK0811065T4 (de) |
ES (1) | ES2271951T5 (de) |
FI (2) | FI120497B (de) |
MX (1) | MX9706294A (de) |
NO (2) | NO321990B1 (de) |
NZ (1) | NZ303843A (de) |
PT (1) | PT811065E (de) |
WO (1) | WO1996026274A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192935B1 (en) * | 1993-03-08 | 2007-03-20 | Amgen Inc. | Polynucleotides encoding epithelium-derived T-cell factor and uses thereof |
US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
JPH09512165A (ja) * | 1994-04-06 | 1997-12-09 | イミュネックス・コーポレーション | インターロイキン15 |
US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
AUPN378095A0 (en) * | 1995-06-23 | 1995-07-20 | Bresagen Limited | Haemopoietic growth factor antagonists and uses therefor |
CA2252557A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of interleukin-15 |
US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
EP1627918A1 (de) * | 1996-04-26 | 2006-02-22 | Beth Israel Deaconess Medical Center, Inc. | Interleukin-15 Antagonisten |
DK0932417T3 (da) * | 1996-10-17 | 2003-04-14 | Immunomedics Inc | Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem |
US5874566A (en) * | 1996-10-25 | 1999-02-23 | Hisamitsu Pharmaceutical Co. Inc. | Il-15 triplex oligonucleotides |
WO1998036768A1 (en) * | 1997-02-21 | 1998-08-27 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Use of interleukin-15 |
CA2332699A1 (en) * | 1998-07-07 | 2000-01-13 | Hisamitsu Pharmaceutical Co., Inc. | Antisense oligonucleotides targeted to il-15 |
GB9814892D0 (en) * | 1998-07-10 | 1998-09-09 | Kennedy Rheumatology Inst | Treatment of celiac disease |
US5985663A (en) * | 1998-11-25 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of interleukin-15 expression |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
MXPA01009074A (es) * | 1999-03-09 | 2002-03-27 | Zymogenetics Inc | Nuevo ligando zalfa11 de citocina. |
AU6689700A (en) * | 1999-07-06 | 2001-01-22 | Silvia Bulfone-Paus | Method of treating psoriasis with il-15 antagonist |
AR025984A1 (es) * | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
CA2408691A1 (en) * | 2000-05-12 | 2001-11-22 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US20020114781A1 (en) | 2000-09-14 | 2002-08-22 | Strom Terry B. | Modulation of IL-2- and IL-15-mediated T cell responses |
US7049069B2 (en) * | 2001-07-17 | 2006-05-23 | University Of Florida | Detecting and treating reproductive tract disorders |
US7329405B2 (en) * | 2001-08-23 | 2008-02-12 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
CA2456648C (en) * | 2001-08-23 | 2011-08-16 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
CN101453332A (zh) * | 2002-04-15 | 2009-06-10 | 株式会社Ntt都科摩 | 利用双线性映射的签名方案 |
CU23093A1 (es) * | 2002-10-09 | 2005-10-19 | Ct Ingenieria Genetica Biotech | Composición vacunal que comprende interleucina-15 (il-15) |
RS20050724A (en) * | 2003-02-26 | 2007-11-15 | Genmab A/S., | Human antibodies specific for interleukin 15(il-15) |
US8604159B2 (en) * | 2003-07-22 | 2013-12-10 | Nektar Therapeutics | Method for preparing functionalized polymers from polymer alcohols |
ES2367027T3 (es) * | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
CU23472A1 (es) * | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
US20060104945A1 (en) * | 2004-10-05 | 2006-05-18 | Choi Yong S | Enhancement of B cell proliferation by IL-15 |
JP5236461B2 (ja) | 2005-05-17 | 2013-07-17 | ユニバーシティ オブ コネチカット | 生物におけるイムノモデュレーションのための組成物および方法 |
EP1777294A1 (de) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine |
US8055951B2 (en) * | 2007-04-10 | 2011-11-08 | International Business Machines Corporation | System, method and computer program product for evaluating a virtual machine |
US8492118B2 (en) | 2007-05-11 | 2013-07-23 | Altor Bioscience Corporation | Fusion molecules and IL-15 variants |
CU23716A1 (es) | 2008-09-30 | 2011-10-05 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la actividad de la interleucina-15 |
US20100145285A1 (en) * | 2008-12-09 | 2010-06-10 | Cook Critical Care, Incorporated | Multi-lumen catheter configuration |
US9487800B2 (en) * | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
EP3327040B1 (de) | 2010-09-21 | 2021-06-23 | Altor BioScience Corporation | Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
EP2665486B1 (de) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Zusammensetzungen zur modulierung einer gamma-c-zytokin-aktivität |
WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
HUE058364T2 (hu) | 2013-04-19 | 2022-07-28 | Cytune Pharma | Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával |
MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
CA3151221A1 (en) | 2014-06-30 | 2016-01-07 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
US10333696B2 (en) | 2015-01-12 | 2019-06-25 | X-Prime, Inc. | Systems and methods for implementing an efficient, scalable homomorphic transformation of encrypted data with minimal data expansion and improved processing efficiency |
US11400134B2 (en) | 2015-10-09 | 2022-08-02 | Bioniz, Llc | Modulating gamma-c-cytokine activity |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
WO2017120479A1 (en) * | 2016-01-07 | 2017-07-13 | The Schepens Eye Research Institute, Inc. | Therapeutics for ocular immunoinflammatory diseases |
AU2017283480A1 (en) | 2016-06-13 | 2019-01-24 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
JP7492336B2 (ja) | 2016-10-21 | 2024-05-29 | アルター・バイオサイエンス・コーポレーション | 多量体il-15に基づく分子 |
IL267113B1 (en) * | 2016-12-21 | 2024-05-01 | Cephalon Llc | Antibodies that bind specifically to human IL-15 and their uses |
CU24546B1 (es) | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
CN111093688A (zh) | 2017-05-15 | 2020-05-01 | 尼克塔治疗公司 | 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 |
AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
CU24545B1 (es) | 2017-12-29 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Péptido antagonista de la actividad de la interleucina-15 |
CN113874075A (zh) | 2019-05-03 | 2021-12-31 | 比奥尼斯有限责任公司 | 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响 |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5071972A (en) | 1986-01-31 | 1991-12-10 | Genetics Institute, Inc. | DNA sequences encoding novel thrombolytic proteins |
EP0276846A3 (de) | 1987-01-29 | 1989-07-26 | Zymogenetics, Inc. | Derivate des koloniestimulierenden Faktors |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
WO1992016221A1 (en) * | 1991-03-15 | 1992-10-01 | Synergen, Inc. | Pegylation of polypeptides |
US5440021A (en) * | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
US5591630A (en) * | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
EP1978033A3 (de) † | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Aus immunisiertem Xenomid abgeleitete menschliche Antikörper |
AU2466895A (en) † | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
-
1995
- 1995-02-22 US US08/392,317 patent/US5795966A/en not_active Expired - Lifetime
-
1996
- 1996-02-21 ES ES96907112T patent/ES2271951T5/es not_active Expired - Lifetime
- 1996-02-21 JP JP8525853A patent/JPH11500908A/ja not_active Withdrawn
- 1996-02-21 NZ NZ303843A patent/NZ303843A/en not_active IP Right Cessation
- 1996-02-21 AU AU50275/96A patent/AU708549B2/en not_active Ceased
- 1996-02-21 KR KR1019970705635A patent/KR19980702238A/ko not_active Application Discontinuation
- 1996-02-21 EP EP96907112A patent/EP0811065B2/de not_active Expired - Lifetime
- 1996-02-21 AT AT96907112T patent/ATE339505T1/de active
- 1996-02-21 MX MX9706294A patent/MX9706294A/es not_active IP Right Cessation
- 1996-02-21 PT PT96907112T patent/PT811065E/pt unknown
- 1996-02-21 DK DK96907112.5T patent/DK0811065T4/da active
- 1996-02-21 WO PCT/US1996/002520 patent/WO1996026274A1/en active IP Right Grant
- 1996-02-21 CA CA2637795A patent/CA2637795C/en not_active Expired - Fee Related
- 1996-02-21 CA CA002210491A patent/CA2210491C/en not_active Expired - Fee Related
- 1996-02-21 DE DE69636538T patent/DE69636538T3/de not_active Expired - Lifetime
- 1996-02-21 EP EP06076615A patent/EP1770163A3/de not_active Withdrawn
-
1997
- 1997-08-12 NO NO19973705A patent/NO321990B1/no not_active IP Right Cessation
- 1997-08-15 FI FI973361A patent/FI120497B/fi not_active IP Right Cessation
-
1998
- 1998-08-14 US US09/134,134 patent/US6165466A/en not_active Expired - Lifetime
- 1998-08-14 US US09/134,132 patent/US6013480A/en not_active Expired - Lifetime
- 1998-08-14 US US09/134,456 patent/US6168783B1/en not_active Expired - Lifetime
- 1998-11-20 US US09/196,427 patent/US6177079B1/en not_active Expired - Lifetime
-
2006
- 2006-01-12 NO NO20060194A patent/NO20060194L/no unknown
- 2006-01-27 FI FI20060080A patent/FI121571B/fi not_active IP Right Cessation
-
2007
- 2007-11-12 JP JP2007293169A patent/JP2008133276A/ja not_active Revoked
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO321990B1 (no) | Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15. | |
US7763434B2 (en) | Antagonists of interleukin-15 | |
CN100467488C (zh) | Il-7融合蛋白 | |
US6270998B1 (en) | DNA coding for human cell surface antigen | |
US20030103936A1 (en) | Method of ex-vivo expansion of hematopoeitic cells using interleukin-3 (IL-3) multiple mutation polypeptides | |
JPH07508179A (ja) | ヒトインターロイキン−13 | |
WO1996023067A1 (en) | Human interleukin-1 receptor accessory protein | |
JP2014156478A (ja) | 哺乳動物のサイトカイン;関連する試薬の使用 | |
Teng et al. | Characterization of chicken interleukin 2 receptor α chain, a homolog to mammalian CD25 | |
US5536657A (en) | Recombinant DNA encoding human receptor for interleukin-12 | |
NZ264003A (en) | Interleukin-12 receptor protein and dna, immunoglobulin capable of binding the protein and pharmaceutical compositions | |
EP0700439A1 (de) | Chemoattraktion auslösender faktor aus lymphozyten und seine verwendungsmöglichkeiten | |
JP3979008B2 (ja) | G−csfレセプターアゴニスト抗体及びそのスクリーニング方法 | |
US20070081979A1 (en) | Multi-functional chimeric hematopoietic receptor agonists | |
KR20230167026A (ko) | Cxcr2 및 gpc3에 대한 star를 공동-발현하는 t 세포, 및 이의 용도 | |
AU751498B2 (en) | flt3 ligand chimeric proteins | |
EP0528928B1 (de) | Interleukin-4-bindeprotein-gamma | |
JPH1189582A (ja) | 炎症性サイトカイン誘導因子の遺伝子 | |
CZ346799A3 (cs) | Chimérické proteiny jako flt3 ligandy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |